TRATAMIENTO DE STRONGYLOIDES
STERCORALIS CON IVERMECTINA Y TIABENDAZOLE
BIBLIOGRAFÍA
1. Vildósola, G. Estrongiloidiasis. Rev Gastroenterol Perú 1997; 17, Supl 1: S75-S91.
2. Huapaya P, Chávez V, Valverde S, Rose M. Prevalencia de Strongyloidiasis en lactantes
y pre-escolares de la Provincia de Chanchamayo. Bol Peruano Parasitol 1995; 11:
32-4.
3. Hernández F. Strongyloides stercoralis: un parásito subestimado. Parasitología al
Día 2001; 25: 40-9.
4. Liñan-Abanto R, Jara C. Frecuencia y aspectos epidemiológicos del parasitismo por
helmintos intestinales en la población infantil de Paiján, La Libertad-Perú. Bol
Peruano Parasitol 1995; 11: 46-50.
5. Vásquez E, Gamero F, Aguirre E. Enteroparasitosis en el asentamiento humano Enrique
Milla Ochoa - Los Olivos. Bol Peruano Parasitol 1995; 11: 55-6.
6. Tantaleán M, Atencia G. Nota sobre parasitismo intestinal diagnosticado en el IMT
Daniel A. Carrión. Rev Per Med Trop UNMSM 1993; 7(2): 99-103.
7. Bannon J, Fater M. Intestinal ileus secondary to Strongyloides stercoralis infection:
case report and review of the literature. Am Surgeon 1995; 61(4): 377-41.
8. Boyd W, Campbell F, Trudeau W. Strongyloides stercoralis - Hyperinfection. Am J Trop
Med Hyg 1978; 27(1): 39-41.
9. Gotuzzo E, Terashima A, Alvarez H, Tello R, Infante R, Watts D, Freedman D.
Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus
type - 1 in Peru. Am J Trop Med Hyg 1999; 60(1): 146-9.
10. Goyal S. Intestinal strongyloidiasis manifesting as eosinophilic pleural effusion.
Southern Med J 1998; 91 (8): 768-70.
11. Herrera J, Herrera J. Estrongiloidiasis: Presentación quirúrgica de dos casos en el
Hospital Central SSPNP - 1988. Rev Sanidad Policía Nac 1989; 50(2): 110-8.
12. Marchesan M, Cardoso R, Anefalos A, Kobayasi S. Invasive enteritis by Strongyloides
stercoralis presenting as acute abdominal distress under corticosteroid therapy. Rev Hosp
Clín Fac Med Sao Paulo 2001; 56 (4): 103-6.
13. Neva F. Biology and immunology of human strongyloidiasis. J Infect Dis 1986; 154(3):
397- 406.
14. Nonaka D, Takaki K, Tanaka M, Umeno M, Takeda T, Yoshida M, et al. Paralitic ileus due
to Strongyloidiasis: case report and review of the literature. Am J Trop Med Hyg 1998;
59(4): 535-8.
15. Shelhamer J, Neva F, Finn D. Persistent Strongyloidiasis in an immunodeficient
patient. Am J Trop Med Hyg 1982; 31(4): 746-51.
16. Terashima A, Gotuzzo E, Alvarez H, Infante R, Tello R, Watts D, Freedman D.
Strongyloides stercoralis: Formas clínicas severas asociadas a infección por HTLV-I. Rev
Gastroenterol Perú 1999; 19(1): 35-40.
17. Datry A, Hilmarsdottir I, Mayorga R, Lyagoubi M, Gaxotte P, Biligui S, et al.
Treatment of Strongyloides stercoralis infections with ivermectin compared with
albendazol: results of an open study of 60 cases. Transact Royal Soc Trop Med Hyg 1994;
88: 344-5.
18. Gann P, Neva F, Gam A. A randomized trial of single and two dose ivermectin versus
thiabendazole for treatment of Strongyloidiasis. J Infect Dis 1994; 169: 1076-9.
19. Lindo J, Atkins N, Lee M, Robinson R, Bundy D. Parasite-specific serum IgG following
successful treatment of endemic strongyloidiasis using ivermectin. Transact Royal Soc Trop
Med Hyg 1996; 90: 702-3.
20. Náquira C, Jimenez G, Guerra J, Bernal R, Nalin D, Neu D, Aziz M. Ivermectin for
human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg 1989; 40(3):
304-9.
21. Shikiya K, Kinjo N, Uehara T, Uechi H, Ohshiro J, Arakaki T, et al. Efficacy of
ivermectin against Strongyloides stercoralis in humans. Internal Med 1993; 31(3): 310-2.
22. Most H, Yoeli M, Campbell W, Cuckler A. The treatment of Strongyloides and Enterobius
infections with thiabendazole. Am J Trop Med Hyg 1965; 14(3): 379-82.
23. Cahill K. Thiabendazol in massive strongyloidiasis. Am J Trop Med Hyg 1967; 16(4):
451-3.
24. Franz K, Schneider, Pohlman M. Clinical trials with thiabendazole against intestinal
nematodes infecting humans. Am J Trop Med Hyg 1965; 14(3): 383-6.
25. Grove D. Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and
effectiveness. Transact Royal Soc Trop Med Hyg 1982; 76(1): 114-8.
26. Portugal R, Schaffel R, Almeida L, Spector N, Nucci M. Thiabendazole for the
prophylaxis of strongyloidiasis in immunosuppressed patients with hematological diseases:
a randomized double-blind placebo-controlled study. Haematol 2002; 87(6): 663-4.
27. Eland IA, Kerkhof SC, Overbosch D, Wismans PJ, Stricker BH. Cholestatic hepatitis
ascribed to the use of thiabendazole. Ned Tijdschr Geneeskd 1998; 142(23): 1331-4.
28. Marron Gasca J, Gimenez Serrano H, Calvo Morales A, Pastor Bajo JA, Aizpun Pon M.
Fixed exanthema induced by thiabendazole. Actas Dermosifiliogr 1976; 67(9-10):
701-6.
29. Tada Y, Fujitani T, Yano N, Yuzawa K, Nagasawa A, Aoki N, et al. Chronic toxicity of
thiabendazole (TBZ) in CD-1 mice. Toxicol 2001; 169(3): 163-76.
30. Terashima A, Alvarez H, Tello R, Infante R, Freedman DO, Gotuzzo E. Treatment failure
in intestinal Strongyloidiasis: an indicator of HTLV-1 infection. Int J Infect Dis 2002;
6(1): 28-30.
31. Davidson, R, Fletcher R, Chapman L. Risk factors for Strongyloidiasis. A case-control
study. Arch Intern Med 1984; 144: 321-4.
32. Godoy P, Camargos C, Costa G, Fonseca L. Associação timoma e strongiloidíase
intestinal grave. Rev Soc Brasileira Med Trop 1998; 31(5): 481-5.
33. Maciel E, Espinheira L, Brites C. Strongyloidiasis as an opportunistic infection in a
HAM/TSP patient. Brazilian J Infect Dis 1999; 3(1): 23-7.
Regresar
|
